title: [Multimodal therapy of dyslipidemia].
abstract: In the multifactorial process of atherogenesis not only increased LDL-cholesterol but also decreased HDL-cholesterol and raised triglycerides correlate closely to cardiovascular events. Multiple studies have demonstrated a high prevalence of dyslipidemia and the metabolic syndrome in Germany.Statins remain first-line therapy for the treatment of dyslipidemia. However, despite therapy a relevant cardiovascular risk remains. Therefore, it is important to also aim for an adequate treatment of hypertriglyceridemia and also to raise HDL-levels. Many combination therapies have been shown to be effective in treating dyslipidemia. Adding Omega-3-fatty acids, nicotinic acid/laropiprant or a fibrate to statin monotherapy provide additional beneficial lipid-modifying effects for combined dyslipidemia. In the future a recommendation for the treatment of mixed hyperlipoproteinemia with decreased HDL, raised triglycerides and LDL-cholesterol shall have to be added to our guidelines.
authors.affiliation: Zentrum für klinische Studien, Fiedlerstraße 34, Dresden, Germany. annett.stahn@gwtonline-zks.de
authors.forename: Annett
authors.initials: A
authors.lastname: Stahn
authors.forename: Markolf
authors.initials: M
authors.lastname: Hanefeld
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D058607:Fibric Acids / Q000627:therapeutic use; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D009525:Niacin / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D015525:Fatty Acids, Omega-3; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007211:Indoles; D008055:Lipids; C518174:MK-0524; D009525:Niacin